1.1Radionuclide in a crystal lattice
Radioactive lutetium occupies lutetium sites in a lutetium phosphate nanocrystal. A functional polymer coating supplies coupling sites for the antibody, which binds its target on the cell surface.
Generated automatically. Not reviewed by a person. Not legal advice or an opinion.
Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.
Radioactive lutetium occupies lutetium sites in a lutetium phosphate nanocrystal. A functional polymer coating supplies coupling sites for the antibody, which binds its target on the cell surface.
A thiol on one linker fragment reacts with a haloacetyl group on the other fragment. The resulting carbon–sulfur bond forms a thioether junction between the fragments.
A single-stranded DNA aptamer folds into a structure that binds a selected cell surface protein. A terminal amine couples the aptamer to a linker bearing a radionuclide chelator.
A discrete linker fragment provides three copies of the repeat unit and carries coupling groups at both ends. One end connects to the targeting component and the other connects to the chelator-bearing component.
An activated ester on a near-infrared fluorophore reacts with an antibody amine to form an amide bond. An imaging system illuminates exposed tissue at the excitation wavelength and records the longer-wavelength emission through an optical filter.
Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.
A zirconium-89 radioimmunoconjugate carries an antibody that binds canine CD20. Serial sections from an excised canine lymph node receive either the tracer alone or the tracer mixed with excess unlabeled antibody. After washing, a phosphor imaging plate records the activity distribution in each section. The difference between the two images maps antibody binding that the unlabeled antibody displaces.
Copper-64 serves as the radionuclide, and a bifunctional cross-bridged cyclam serves as the chelator. A pendant carboxyl group on the chelator couples to an amine at the end of the antibody linker, leaving the metal-binding donor atoms available for copper coordination. The chelator-linker intermediate binds copper-64 before coupling to the antibody, and size-exclusion chromatography separates the conjugate from residual labeled intermediate.
A recombinant antigen-binding antibody fragment replaces the intact antibody and carries an engineered cysteine at the end of its heavy chain. A linker with a terminal maleimide couples the chelator to that cysteine, producing a conjugate with a single attachment site. The chelator coordinates the selected radiometal, and size-exclusion chromatography separates the labeled fragment from low-molecular-weight radiometal species.
Eight shielded reaction vials each hold 100 µL of the same chelator-bearing antibody and radionuclide mixture. Two vials react at each of four time points, 5, 15, 30, and 60 minutes, at a constant temperature. At each time point, a soluble scavenger for the selected metal captures unbound radionuclide, and radioactivity-detected size-exclusion chromatography measures the fraction associated with the antibody.
An integrated PET and magnetic resonance scanner acquires a zirconium-89 radioimmunoconjugate activity map and anatomical images during the same session. The scanner geometry places both datasets in a common coordinate system, and the reconstruction software resamples the PET map onto the anatomical image grid. Software transfers lesion boundaries drawn on the anatomical images to the activity map and reports the mean activity concentration within each lesion.
An autosampler injects an aliquot of the radioimmunoconjugate onto a size-exclusion column connected in series to ultraviolet and radioactivity detectors. Software aligns the two traces using the transit time between detectors and applies retention windows established with antibody monomer and aggregate controls. It integrates the monomer radioactivity peak and divides that value by the total eluted radioactivity to report the monomer-associated fraction.
A bifunctional tetraaza macrocycle carries four pendant acetate groups and a separate isothiocyanate coupling group. The coupling group reacts with an antibody lysine to form a thiourea bond, and the macrocyclic nitrogens and carboxylate oxygens coordinate lutetium.
A divalent oxygen atom joins two carbon atoms at the Y position. Alkylation of an alcohol-terminated linker fragment with a primary alkyl halide forms the ether junction.
The segment indexed by m contains three repeat units. A discrete linker precursor supplies the three-unit segment with terminal groups for coupling to the adjacent components.
Zirconium-89 supplies the positron emission signal and has a physical half-life of about 78 hours. A positron emission scanner detects coincident annihilation photons to map tracer distribution over multiple days.
Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.
Unlike many prior compositions for the preparation of targeted radiopharmaceuticals, the radiopharmaceutical formulations of the invention utilize a small amount of chelator/targeting molecule conjugate (e.g., compounds of Formula I).A · US 7,556,795 B2 · ¶ 16
Also provided are radiometal complexes containing an alpha-emitting radiometal ion bound to the macrocyclic chelator via coordinate bonding, and radioimmunoconjugates containing the radiometal complexes covalently linked to a targeting ligand, such as an antibody or antigen binding fragment thereof.B · US 2020/0353105 A1 · abstract
The targeting molecule may also be an antibody, such as, for example, a monoclonal or polyclonal antibody or a fragment thereof.A · US 7,556,795 B2 · ¶ 36
Also provided are radiometal complexes containing an alpha-emitting radiometal ion bound to the macrocyclic chelator via coordinate bonding, and radioimmunoconjugates containing the radiometal complexes covalently linked to a targeting ligand, such as an antibody or antigen binding fragment thereof.B · US 2020/0353105 A1 · abstract
The spacer may also include a hydrocarbon chain (i.e., —R1—(CH2)n—R2—) wherein n is 0-10, preferably n=3 to 9, R1 is a derivative of a group (e.g., H2N—, HS—, —COOH) that can be used as a site for covalently linking the ligand backbone or the preformed metal chelator or metal complexing backbone; and R2 is a group that is used for covalent coupling to the N-terminal NH2-group of the methods for conjugating ligands (i.e., chelators) or preferred metal chelates to biomoleculesA · US 7,556,795 B2 · ¶ 41
wherein R1 is H or is a linear or branched, saturated or unsaturated C1-4 alkyl chain that is optionally interrupted by one or two heteroatoms selected from N, O and S; and is optionally substituted by at least one group selected from halogen, hydroxyl, amino, carboxyl, C1-4 alkyl, aryl and C(O)Z;A · US 7,556,795 B2 · ¶ 9
The preferred radioisotope used for the preparation of radiopharmaceuticals made with the present formulation are isotopes of technetium and rhenium (e.g., 94Tc, 99mTc, 186Re, 188Re).A · US 7,556,795 B2 · ¶ 27
Preferably, a radiometal ion used in the invention is an alpha-emitting radiometal ion, such as actinium-225 (225Ac).B · US 2020/0353105 A1 · ¶ 208
Also provided are radiometal complexes containing an alpha-emitting radiometal ion bound to the macrocyclic chelator via coordinate bonding, and radioimmunoconjugates containing the radiometal complexes covalently linked to a targeting ligand, such as an antibody or antigen binding fragment thereof.B · US 2020/0353105 A1 · abstract
An empty cell means only that no passage was reproduced there.
One problem frequently encountered is that many formulations require a high concentration of the targeted chelating ligand in reactions for the preparation of a targeted radiopharmaceutical to assure high yields of the desired complex.A · US 7,556,795 B2 · ¶ 4
It would be highly advantageous to have a formulation for the preparation of this and other receptor-binding targeted radiopharmaceuticals that, among other things, can be used clinically (e.g., directly injected) without the need for HPLC purification.A · US 7,556,795 B2 · ¶ 6
Accordingly, there is a need in the art for novel chelators that bind radiometals, preferably alpha-emitting radiometals, such as actinium-225 (225Ac), and can be used to produce stable radioimmunoconjugates with high specific activity and high yield.B · US 2020/0353105 A1 · ¶ 7
The invention satisfies this need by providing a macrocyclic chelator capable of binding radiometals, such as alpha-emitting radiometals, particularly 225Ac, irrespective of the specific activity or most common metal impurities.B · US 2020/0353105 A1 · ¶ 7
patent.fyi, US 2026/0355364 A1, claim 1, first published 2026-11-19T10:32:39-05:00, https://patent.fyi/US20260355364/, SHA-256 244c7e8e6d372258d2c0e0c99774d5b6f9256bce2fc8475fddf8d1a1054fe569